3DMed adopts biomarker-driven drug development strategy.

With the largest PDC HCC library, we are capable of conducting drug screening in hundreds of human tumor cell lines with clear genome information, mimicking "clinical trials" in the cancer patient population even in the early preclinical stage.

With the NGS platform, we are capable of acquiring and analyzing the genomic profiles of the PDC cell lines and develop NGS biomarkers for patient stratification.

With the Oncology Data Service Platform, we are capable of predicting the patient response rate and optimizing clinical trial design to improve the success rate in clinical development.